Canadian Cardiovascular Society

CCS-BMS Hypertrophic Cardiomyopathy (HCM) Research Award

The Canadian Cardiovascular Society and Bristol Myers Squibb (BMS) are proud to support the CCS-BMS Hypertrophic Cardiomyopathy (HCM) Research Award. The purpose of this award is to foster growth of peer-reviewed Canadian research in the area of HCM, with a focus on HCM diagnosis, progression monitoring, epidemiology and / or prevalence.

2022 Call for Applications: Closes March 9th, 2022 at 11:59 PM EST

Full details on the award and application process can be found in the CCS-BMS HCM Research Award Handbook


Eligibility

  • Be a CCS Member. For more information about CCS Membership, visit the CCS website: http://www.ccs.ca/en/membership
  • Applicants must be a Canadian Citizen or Permanent Resident of Canada. 
  • The principal investigator must be an early career independent researcher (within 5 years of their first clinical appointment at a Canadian academic institution). Co-applicants of different career stages can be included. Inclusion of at least one mid-career or senior investigator serving as mentor is strongly encouraged. 
  • Applicants can be principal investigators on only one application. 
  • Award funds are solely intended for research performed in Canada. 
  • The award and funds are intended for original research that is either clinical or translational with expected impact of HCM patient care. Proposal should not request supplement funding for an ongoing project.   
    • If the submission refers to a multicenter clinical trial, the applicant must specify their specific role in the research study.  
    • If the application is for a sub-study of an ongoing project or trial, the applicant must specify their role and explain how the sub-study is distinct from the main study. 
  •  Funded research must be completed within 48 months from the start of funding. 
  •  Research status report will be requested and should be submitted on October 1st of the ensuing year(s) that the project is running. 

Eligible areas of research

Eligible research includes all areas of HCM, with preferential focus on HCM diagnosis, progression monitoring, epidemiology and / or prevalence. Should the study be clinical in nature, please outline how you will emphasize equity, diversity and inclusion in patient populations.

The Award

Two (2) awards of up to $70K each will be awarded based on an independent peer review process.  A total of $132K in funding is available across the two awards.  
Award funds will be administered by the Research Center or Cardiology Division of the awardee’s affiliated university or equivalent. 

Budget Template

Download the 2022 Budget template here.

The Peer Review Process and Evaluation Committee

All applications will be pre-screened for eligibility. Applications that are late, incorrectly formatted, incomplete and/or do not meet the basic eligibility criteria will not be considered for review.

Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS members. Reviewers are selected for their subject matter expertise. All eligible proposals will be reviewed by at least three members of the peer review committee. All applicants will receive feedback from reviewers, upon request.


If you have any questions or require support preparing or submitting your application, please email researchawards@ccs.ca.

Supported by:

The Canadian Cardiovascular Society and BMS are proud to support the CCS-BMS HCM Research Award. With this award, we hope to further research on hypertrophic cardiomyopathy to improve the lives of Canadians who are affected by this condition, and their families.

Back to top